BiovelocITA is the first Italian accelerator of promising biotech projects in several therapeutic areas.

BiovelocITA supports the creation and development of innovative biotech start-ups, from proof of concept to clinical phases, that could make the difference for the medical community and patients.
Founded by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners, BiovelocITA has accelerated several programs so far collaborating with world-class Italian scientists. Two of them, Enthera and Alia, received a direct investment from Atlante Seed.

BiovelocITA entered in Atlante Seed’s portfolio in 2016.